Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy

Slyker Jennifer A<sup>*</sup>; Casper Corey; Tapia Kenneth; Richardson Barbra; Bunts Lisa; Huang Meei Li; Wamalwa Dalton; Benki Nugent Sarah; John Stewart Grace

doi:10.1093/cid/ciu088

登录

免费注册

赞收藏引用

科研之友

微信

新浪微博

Facebook

分享链接

Accelerated Suppression of Primary Epstein-Barr Virus Infection in HIV-Infected Infants Initiating Lopinavir/Ritonavir-Based Versus Nevirapine-Based Combination Antiretroviral Therapy

作者：Slyker Jennifer A^*; Casper Corey; Tapia Kenneth; Richardson Barbra; Bunts Lisa; Huang Meei Li; Wamalwa Dalton; Benki Nugent Sarah; John Stewart Grace

来源：Clinical Infectious Diseases, 2014, 58(9): 1333-1337.

DOI：10.1093/cid/ciu088

摘要

We compared primary Epstein-Barr virus (EBV) infection and suppression between Kenyan human immunodeficiency virus-infected infants starting nevirapine-based vs lopinavir/ritonavir-based antiretroviral regimens. Although the rate of EBV infection was similar between groups, infants receiving lopinavir/ritonavir suppressed EBV more rapidly. Our findings suggest that specific antiretrovirals may potentially impact the risk of future EBV-associated malignancies.